<?xml version="1.0" encoding="UTF-8"?>
<p id="para0068">Lopinavir/ritonavir have major interactions with drugs used in cardiovascular diseases such as anti-coagulating agents (anti-factor Xa inhibitors), none dihydropyridine calcium channel blockers, digoxin, antiarrhythmic agents such as amiodarone, etc. So close patient monitoring is required in COVID-19 patients with pre-existing cardiovascular disease who are planned to treat with lopinavir/ritonavir and sometimes alternative drugs might be considered.
 <xref rid="bib0052" ref-type="bibr">
  <sup>52</sup>
 </xref>
</p>
